Who
Roy D. Baynes
Director
Company insider
Files Form 4 as: Director, Aardvark Therapeutics; Director, Natera; Director, Travere Therapeutics; Director, Nurix Therapeutics; Chief Medical Officer, Eikon Therapeutics; Director, Atara Biotherapeutics.
In numbers
- Trades disclosed
- 164
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $14.0M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 19 Jul 2016
- Last trade
- 14 Aug 2026
- Last filed
- 21 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Aug 2026filed 21 Aug 2026 | AARD Aardvark Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,964 at $0.00 | filing |
| 14 Aug 2026filed 21 Aug 2026 | AARD Aardvark Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,964 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Code A | —1,571 | filing |
| 26 Jun 2026filed 30 Jun 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Code A | —75 | filing |
| 26 Jun 2026filed 30 Jun 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Code A | —1,571 | filing |
| 26 Jun 2026filed 30 Jun 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Code A | —75 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $96K4,500 at $21.38 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $225K4,500 at $50.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,500 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,500 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $96K4,500 at $21.38 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $225K4,500 at $50.00 | filing |
| 19 May 2026filed 21 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 15 May 2026filed 15 May 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,250 at $0.00 | filing |
| 15 May 2026filed 15 May 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,250 at $0.00 | filing |
| 5 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $82K4,500 at $18.27 | filing |
| 5 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $210K4,500 at $46.65 | filing |
News
Natera (NTRA) Is Expanding Cancer Testing Rapidly. Does Its Valuation Leave Room for Error?NTRA · insidermonkey.com · 20 Oct 2026Travere (NASDAQ: TVTX) CEO sells 243,735 shares after option exercisesTVTX · dailypolitical.com · 19 Oct 2026ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology | wallstreetONLINENTRA · wallstreet-online.de · 19 Oct 2026Curated Wealth Partners LLC Purchases 2,195 Shares of Natera, Inc. $NTRANTRA · dailypolitical.com · 16 Oct 2026
0 headlines in the last 90 days name Roy D. Baynes; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.